infT )) -( (-ke
Exp
Css
Css
trough peak)
(
peakCss
MIC
LN
CL
Vd
-y
)
(
infT
Dose/CL
f
-Css
infT
Dose/CL
f
-MIC
LN
CL
Vd
infT
x
trough100
y
x
MIC
T
)
Exp
-(1
infT
CL
)
Exp
-(1
Dose
f
Css
) (-ke infT) ke -(1 peak)
Exp(
P
1) Craig W A, Pharmacokinetic/pharmacodynamic parameters, rationale for antibac-terial dosing of mice and men. Clin. Infect. Dis, 1998; 26: 1-12.
2) Andes A, Craig W A, Understanding pharmacokinetics and pharmacodynamics, application to the antimicrobial formulary decision process. Marcel Dekker New York, 2005; 65-88.
3) Kuti J L, Dandekar P, Nightingale C H, Nicolau D P, Use of monte carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 2003; 43: 1116-1123.
4) Kuti J L, Nightingale C H, Nicolau D P, Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram, Data collected in North America in 2002. Antimicrobial. Agents Chemotherapy. 2004; 48 7: 2464-2470. 5) , , , , , , tazobactam/piperacillin ( 1:8 ) , , 2010; 58(S-1): 11-28. 6) , , , Tazobactam/Piperacillin , Chemotherapy, 1994; 42(S-2): 206-216.
7) Jaruratanasirikul S, Sriwiriyajan S, Punyo J, Comparison of the pharmacodynamics of mero-penem in patients with ventilator-associated pneumonia following administration by 3-hour infu-sion or bolus injection. J. Antimicrob. Chemother, 2005; 49: 1337-1339.
PK/PD , 2011; 37(6): 335-344. 9) , , , , PK/PD , 2006. 10) PK/PD , PK/PD , , 2016; 64: 139-151. 11) , : ( 2005 ), , 2005; 53: 557-9.
12) Clinical and Laboratory Standards Institute, Performance standards for anti-microbial suscep-tibility testing; Twenty-fifth informational supplement M100-S25. CLSI, Wayne, Pennsylvania, 2015.
13) Cockcroft D W, Gault M H, Nephron, 1976; 16: 31-34.
14) , piperacillin , , 2003;
